The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

Background Analysis of myeloid-related protein 8 and 14 complex (MRP8/14) serum concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile idiopathic arthritis (SJIA) in the presence of fever of unknown origin. Objective To test the ability of MRP8/14 serum concentrat...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 71; no. 6; pp. 974 - 980
Main Authors Holzinger, Dirk, Frosch, Michael, Kastrup, Astrid, Prince, Femke H M, Otten, Marieke H, Van Suijlekom-Smit, Lisette W A, Cate, Rebecca ten, Hoppenreijs, Esther P A H, Hansmann, Sandra, Moncrieffe, Halima, Ursu, Simona, Wedderburn, Lucy R, Roth, Johannes, Foell, Dirk, Wittkowski, Helmut
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2012
BMJ Publishing Group
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0003-4967
1468-2060
1468-2060
DOI10.1136/annrheumdis-2011-200598

Cover

More Information
Summary:Background Analysis of myeloid-related protein 8 and 14 complex (MRP8/14) serum concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile idiopathic arthritis (SJIA) in the presence of fever of unknown origin. Objective To test the ability of MRP8/14 serum concentrations to monitor disease activity in patients with SJIA and stratify patients at risk of relapse. Methods Serum concentrations of MRP8/14 in 52 patients with SJIA were determined by a sandwich ELISA. The monitoring of therapeutic regimens targeting interleukin 1 and tumour necrosis factor α, and methotrexate treatment was analysed and diagnostic power to predict flares was tested. Results MRP8/14 levels were clearly raised in active disease and decreased significantly in response to successful treatments. Serum concentrations of MRP8/14 increased significantly (p<0.001) (mean±95% CI 12.030±3.090 ng/ml) during disease flares compared with patients with inactive disease (864±86 ng/ml). During clinical remission MRP8/14 serum levels of >740 ng/ml predicted disease flares accurately (sensitivity 92%, specificity 88%). MRP8/14 levels correlated well with clinical disease activity, as assessed by physician's global assessment of disease activity (r=0.62), Childhood Health Assessment Questionnaire (r=0.56), active joint count (r=0.46) and with C-reactive protein (r=0.71) and erythrocyte sedimentation rate (r=0.72) (for all p<0.001). Conclusion MRP8/14 serum concentrations correlate closely with response to drug treatment and disease activity and therefore might be an additional measurement for monitoring anti-inflammatory treatment of individual patients with SJIA. MRP8/14 serum concentrations are the first predictive biomarker indicating subclinical disease activity and stratifying patients at risk of relapse during times of clinically inactive disease.
Bibliography:ArticleID:annrheumdis-2011-200598
istex:5E814BCE8365FC900B65038CB28A0FEDA335C5E4
PMID:22267331
local:annrheumdis;71/6/974
ark:/67375/NVC-TD634SZ2-4
href:annrheumdis-71-974.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/annrheumdis-2011-200598